News
Drug Development
FDA
Drug Delivery
Deals
Business
Policy
Cell and Gene Therapy
Weight Loss
Rare Disease
Cancer
Job Trends
Artificial Intelligence
NextGen: Top Start Ups to Watch
Podcasts
Reports
Webinars
Press Releases
All News & Releases
Insights
Jobs
Career Advice
Companies
Hotbeds
More
Best Places to Work
Employer Resources
Post Jobs
Talent Solutions
Advertise
Submit a Press Release
SUBSCRIBE
Menu
SUBSCRIBE
Show Search
News
Drug Development
FDA
Drug Delivery
Deals
Business
Policy
Cell and Gene Therapy
Weight Loss
Rare Disease
Cancer
Job Trends
Artificial Intelligence
NextGen: Top Start Ups to Watch
Podcasts
Reports
Webinars
Press Releases
All News & Releases
Insights
Jobs
Career Advice
Companies
Hotbeds
More
Best Places to Work
Employer Resources
Post Jobs
Talent Solutions
Advertise
Submit a Press Release
Search Query
Submit Search
Search Results
Submit
Looking for jobs?
Search jobs
Close
258,958 Results
Type
Article (13827)
Company Profile (293)
Press Release (244838)
Section
Business (79301)
Career Advice (147)
Deals (13176)
Drug Delivery (31)
Drug Development (50262)
Employer Resources (31)
FDA (5668)
Job Trends (5108)
News (144017)
Policy (10013)
Tag
Academia (901)
Alliances (21438)
Alzheimer's disease (729)
Approvals (5631)
Artificial intelligence (59)
Bankruptcy (97)
Best Places to Work (4457)
Biotechnology (241)
Breast cancer (57)
Cancer (574)
Cardiovascular disease (52)
Career advice (128)
CAR-T (44)
Cell therapy (149)
Clinical research (39582)
Collaboration (202)
Compensation (83)
COVID-19 (998)
C-suite (53)
Cystic fibrosis (61)
Data (612)
Diabetes (64)
Diagnostics (1191)
Earnings (28581)
Events (46508)
Executive appointments (154)
FDA (5911)
Funding (207)
Gene editing (48)
Gene therapy (127)
GLP-1 (290)
Government (1063)
Healthcare (6527)
Infectious disease (1027)
Inflammatory bowel disease (89)
IPO (7168)
Job creations (859)
Job search strategy (124)
Layoffs (181)
Legal (1372)
Lung cancer (101)
Manufacturing (66)
Medical device (2547)
Medtech (2548)
Mergers & acquisitions (6087)
Metabolic disorders (203)
Neuroscience (909)
NextGen Class of 2024 (1996)
Non-profit (841)
Northern California (783)
Obesity (117)
Opinion (90)
Parkinson's disease (55)
Patents (45)
People (24888)
Pharmaceutical (48)
Phase I (13911)
Phase II (18405)
Phase III (11681)
Pipeline (139)
Postmarket research (846)
Preclinical (5872)
Radiopharmaceuticals (203)
Rare diseases (140)
Real estate (1409)
Regulatory (8159)
Research institute (930)
Southern California (725)
Startups (1963)
United States (6586)
Vaccines (153)
Weight loss (74)
Date
Today (143)
Last 7 days (517)
Last 30 days (1828)
Last 365 days (20675)
2024 (17687)
2023 (22412)
2022 (26822)
2021 (27806)
2020 (23357)
2019 (16224)
2018 (11738)
2017 (13745)
2016 (11839)
2015 (14349)
2014 (10392)
2013 (7484)
2012 (7532)
2011 (7614)
2010 (7428)
Location
Africa (146)
Asia (16764)
Australia (2819)
California (1777)
Canada (645)
China (134)
Colorado (65)
Connecticut (71)
Europe (36077)
Florida (191)
Georgia (51)
Illinois (111)
Indiana (51)
Kansas (54)
Maryland (261)
Massachusetts (1479)
Michigan (45)
Minnesota (82)
New Jersey (482)
New York (541)
North Carolina (381)
Northern California (783)
Ohio (72)
Pennsylvania (374)
South America (207)
Southern California (725)
Texas (181)
Washington State (197)
258,958 Results for "evecxia therapeutics".
Filters
Sort By
Relevance
Relevance
Newest
Oldest
Press Releases
Evecxia Therapeutics ACCESS CHINA Partnering Forum
September 19, 2024
·
1 min read
News
Evecxia Therapeutics Announces Successful Completion of Pre-IND Meeting with the FDA Regarding Development of EVX-101 For Depression
October 25, 2024
·
4 min read
Business
Evecxia Therapeutics Announces CEO Transition
Evecxia Therapeutics, Inc., the leader in serotonin synthesis amplification to treat brain disorders, today announced that Dr. Jacob Jacobsen has been appointed President and CEO.
September 14, 2023
·
2 min read
Business
Evecxia Therapeutics Strengthens Board of Directors With Appointments of Allan L. Shaw and Elliot Ehrich
Evecxia Therapeutics, Inc. today announced the appointments of Allan L. Shaw and Elliot Ehrich, MD to its Board of Directors, bringing with them decades of leadership experience in the biopharmaceutical industry.
October 30, 2023
·
4 min read
Bio NC
Evecxia Therapeutics Reports No Toxicology Findings in Nonclinical GLP Studies of Adjunctive EVX-101
Evecxia Therapeutics, Inc., the leader in serotonin synthesis amplification to treat brain disorders, today announced the absence of toxicity findings associated with the co-administration of EVX-101 in conjunction with the first-line antidepressant fluoxetine in nonclinical GLP toxicology studies.
October 2, 2023
·
4 min read
Bio NC
Evecxia Therapeutics Receives Notice Of Allowance For A U.S. Patent Covering Its Lead Drug Candidate EVX‑101
Evecxia Therapeutics, Inc. today announced that the U.S. Patent and Trademark Office has allowed U.S. patent application 17/877,699.
April 28, 2023
·
2 min read
Bio NC
Evecxia Therapeutics Announces Data Presentations on Lead Candidate EVX-101 at the 2023 American Society of Clinical Psychopharmacology (ASCP) Annual Meeting
Evecxia Therapeutics, Inc. today announced that an oral presentation, “The Therapeutic Potential of EVX-101 to Amplify Serotonin Synthesis for the Adjunctive Treatment of MDD and Other Mental Illness: Emerging Profile and Post-Phase 1 Update”, will be presented during the Pharmaceutical Pipeline Session on May 30th by Dr. Jacobson, Chief Scientific Officer, at the 2023 ASCP Meeting in Miami Beach, FL.
May 25, 2023
·
2 min read
Drug Development
Evecxia Therapeutics Reports Favorable Data From a Phase 1 Single Ascending Dose Safety/Tolerability/PK/PD Trial of EVX-301
Evecxia Therapeutics, Inc. announced favorable safety, tolerability, pharmacokinetics, and pharmacodynamics data from a double-blind, placebo-controlled Phase 1 single ascending dose study of EVX-301 in healthy volunteers pre-treated with escitalopram for three weeks.
March 15, 2023
·
4 min read
Drug Development
Evecxia Therapeutics Reports Favorable Data From a Phase 1 Single-Ascending Dose and Multiple-Ascending Dose Trial of Adjunctive EVX-101 in Healthy Volunteers Treated With a First-Line Antidepressant
Evecxia Therapeutics, Inc. today announced favorable safety, tolerability, pharmacokinetic, and pharmacodynamic data from a double-blind, placebo-controlled Phase 1, a two-part single ascending dose (SAD) and multiple ascending dose (MAD) trial of EVX-101 in healthy volunteers treated with escitalopram.
April 10, 2023
·
5 min read
Business
Evecxia Therapeutics Announces Leadership Transition to Support Next Phase of Development and Growth
Evecxia Therapeutics, a clinical stage biopharmaceutical company dedicated to realizing the therapeutic potential of serotonin synthesis amplification for the treatment of brain disorders, today announced that Joseph M. Patti, Ph.D., has been appointed President and Chief Executive Officer.
June 13, 2022
·
4 min read
1 of 25,896
Next